Physician profile
Don G Aaron
NPI 1477656874
$1,396.40
in general payments reported to CMS, 2019-2025
12 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $111 · 2021: $202 · 2022: $238 · 2023: $99.61 · 2024: $321 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,131.51 | 2019-2025 | Real Intelligence, Spatial Frame, Bone Anchors With Arthroscopic Delivery System |
| Vericel Corporation | $40.03 | 2022-2024 | Maci |
| Bioventus LLC | $38.47 | 2019 | |
| Stryker Corporation | $30.88 | 2019 | |
| Depuy Synthes Sales INC. | $28.24 | 2019-2020 | |
| Pacira Therapeutics, INC. | $27.70 | 2019 | |
| Amgen INC. | $22.31 | 2025 | Krystexxa |
| Horizon Therapeutics Plc | $22.18 | 2019-2020 | |
| Kci USA, INC. | $14.31 | 2021 | |
| Dynasplint Systems INC. | $14.16 | 2025 | Dynasplint |
| Abbott Laboratories | $13.96 | 2020 | |
| Medacta USA, INC. | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.